PAVmed Provides Update on CarpX™ Clinical Safety Study
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its CarpX™ first-in-human (FIH) 510(k) clinical safety study. This week, senior PAVmed personnel met with the local investigators in New Zealand and completed an on-site review of the study data. Full 90-day follow-up is now 90% complete (18 of 20 patients) and 90-day clinical follow-up is 95% complete (19 of 20 patients) – with one patient completing clinical follow-up but not yet completing electrodiagnostic testing. The research team continues to pursue the two incomplete follow-up patients. The study has, however, already exceeded the minimum 80% follow-up rate requested by the U.S. Food and Drug Administration (FDA) with no device-related adverse events. The team has concluded that the device appears to have met the study’s primary effectiveness and safety endpoints. PAVmed is now pr
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]Yahoo! Finance
- PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring [Yahoo! Finance]Yahoo! Finance
- PAVmed Inc. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- PAVmed Provides Business Update and Third Quarter 2024 Financial ResultsPR Newswire
PAVM
Earnings
- 11/14/24 - Beat
PAVM
Analyst Actions
- 9/10/24 - Ascendiant Capital
PAVM
Sec Filings
- 11/21/24 - Form PRE
- 11/21/24 - Form 8-K
- 11/14/24 - Form SC
- PAVM's page on the SEC website